EAST BRUNSWICK, N.J., Dec. 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming 27th Annual J.P. Morgan Healthcare Conference.
Advertisement
The presentation is scheduled to begin on Wednesday, January 14, 2009 at 4:00 p.m. PT. The Conference will be held at the Westin St. Francis Hotel in San Francisco, CA January 11-15, 2009.
Advertisement
Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.
SVNT-G
Contact: Mary Coleman Director, Investor Relations Savient Pharmaceuticals, Inc. [email protected] (732) 418-9300
SOURCE Savient Pharmaceuticals, Inc.
